Last updated: 2026-09-06 01:35:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Sol-Gel Technologies Ltd. (SLGL) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $69,36, with a market capitalization of $230,59M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $22,67 to $97,97. This page covers its latest market performance, valuation, price trends and company information.
$230,59M | |
$70,17 | |
$210,00 | |
$3,34 | |
$70,10 | |
27,91K | |
-- | |
-- | |
$97,97 | |
$22,67 | |
-- | |
-- |
Sol-Gel Technologies Ltd. (SLGL) last closed at $70,10 as of 2026-09-04 22:10:00, unchanged from the previous close of $70,10.
During the latest regular trading session, SLGL traded between $3,34 and $210,00, with a volume of 27,91K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Sol-Gel Technologies Ltd. (SLGL) moved from $67,77 to $69,36, representing a gain of 2,34% ($1,59).
The stock traded between $68,14 and $72,15 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 90,52 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 62,0%
SLGL is currently trading at $69,36, placing it 62,0% of the way from its 52-week low of $22,67 to its 52-week high of $97,97. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
| Employees | 28 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Sol-Gel Technologies Ltd. (SLGL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.